<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029013</url>
  </required_header>
  <id_info>
    <org_study_id>ACSTCC</org_study_id>
    <nct_id>NCT03029013</nct_id>
  </id_info>
  <brief_title>Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer</brief_title>
  <official_title>A Phase II Clinical Trial Study on Apatinib and Chemotherapy Sequential Treatment With Advanced Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <brief_summary>
    <textblock>
      The study is the single arm and single center clinical trials，We conduct the phase II&#xD;
      clinical trial to further explore the efficacy and safety of Apatinib and chemotherapy&#xD;
      sequential treatment with advanced recurrence of metastatic cervical cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The pathological diagnosis of recurrent or metastatic cervical cancer;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1;&#xD;
&#xD;
          -  Life expectancy of more than 3months;&#xD;
&#xD;
          -  With normal marrow, liver and renal function：&#xD;
&#xD;
               -  blood routine examination ：HB≥90g/L，ANC ≥1.5×10*9/L，PLT≥80×10*9/L；&#xD;
&#xD;
               -  Biochemical examination: total bilirubin (TBil) of ≤1.5 upper normal limitation&#xD;
                  (UNL)，alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of ≤2.5&#xD;
                  UNL or ≤5 UNL ，acreatinine (Cr) of ≤ 1.25 UNL; creatinine clearance rate ≥&#xD;
                  45ml/min (Cockcroft-Gault);&#xD;
&#xD;
          -  With written informed consent signed voluntarily by patients themselves .&#xD;
&#xD;
          -  With good compliance and agree to accept follow-up of disease progression and adverse&#xD;
             events.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Suffered from grade II or above myocardial ischemia or myocardial infarction,&#xD;
             uncontrolled arrhythmias&#xD;
&#xD;
          -  With abnormal coagulation function， bleeding tendency or treating with thrombolysis&#xD;
             and anticoagulation&#xD;
&#xD;
          -  History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage,&#xD;
             bleeding ulcer, occult blood ≥ (++), and vasculitis) =&lt; 3 months prior to&#xD;
             randomization;&#xD;
&#xD;
          -  uncured the wound or fracture&#xD;
&#xD;
          -  Centrally located tumors of local invasion of major blood vessels, or Researchers&#xD;
             think that patients may invade the important blood vessels and cause fatal bleeding&#xD;
             (CT or MRI);&#xD;
&#xD;
          -  Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and&#xD;
             intestinal obstruction);&#xD;
&#xD;
          -  Urine protein &gt;++, or urine protein in 24 hours&gt; 1.0g&#xD;
&#xD;
          -  Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac&#xD;
             effusion) requiring treatment&#xD;
&#xD;
          -  History of uncontrolled psychotropic drug abuse or mental disorders;&#xD;
&#xD;
          -  Prior VEGFR inhibitor treatment ;&#xD;
&#xD;
          -  Other malignancy within Before or at the same time other than basal cell skin cancer,&#xD;
             or carcinoma in situ of the cervix;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Feng, MD</last_name>
    <phone>86-13908315698</phone>
    <email>wanggedaping@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Jin, M.D.</last_name>
      <phone>86-13908315698</phone>
      <email>wanggedaping@163.com</email>
    </contact>
    <investigator>
      <last_name>Ge Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Jin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Ge Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

